255 related articles for article (PubMed ID: 37834466)
1. Novel Approaches to Treatment of Acute Myeloid Leukemia Relapse Post Allogeneic Stem Cell Transplantation.
Liberatore C; Di Ianni M
Int J Mol Sci; 2023 Oct; 24(19):. PubMed ID: 37834466
[TBL] [Abstract][Full Text] [Related]
2. Treatment of Relapsed Acute Myeloid Leukemia.
Thol F; Ganser A
Curr Treat Options Oncol; 2020 Jun; 21(8):66. PubMed ID: 32601974
[TBL] [Abstract][Full Text] [Related]
3. Relapse after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia: an overview of prevention and treatment.
Kreidieh F; Abou Dalle I; Moukalled N; El-Cheikh J; Brissot E; Mohty M; Bazarbachi A
Int J Hematol; 2022 Sep; 116(3):330-340. PubMed ID: 35841458
[TBL] [Abstract][Full Text] [Related]
4. High rate of hematological responses to sorafenib in FLT3-ITD acute myeloid leukemia relapsed after allogeneic hematopoietic stem cell transplantation.
De Freitas T; Marktel S; Piemontese S; Carrabba MG; Tresoldi C; Messina C; Lupo Stanghellini MT; Assanelli A; Corti C; Bernardi M; Peccatori J; Vago L; Ciceri F
Eur J Haematol; 2016 Jun; 96(6):629-36. PubMed ID: 26260140
[TBL] [Abstract][Full Text] [Related]
5. Hypomethylating Agents and FLT3 Inhibitors As Maintenance Treatment for Acute Myeloid Leukemia and Myelodysplastic Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation-A Systematic Review and Meta-Analysis.
Bewersdorf JP; Allen C; Mirza AS; Grimshaw AA; Giri S; Podoltsev NA; Gowda L; Cho C; Tallman MS; Zeidan AM; Stahl M
Transplant Cell Ther; 2021 Dec; 27(12):997.e1-997.e11. PubMed ID: 34551341
[TBL] [Abstract][Full Text] [Related]
6. Sorafenib Therapy Is Associated with Improved Outcomes for FMS-like Tyrosine Kinase 3 Internal Tandem Duplication Acute Myeloid Leukemia Relapsing after Allogeneic Hematopoietic Stem Cell Transplantation.
Xuan L; Wang Y; Chen J; Jiang E; Gao L; Wu B; Deng L; Liang X; Huang F; Fan Z; Tang X; Sun J; Zhang X; Han M; Wu D; Huang X; Liu Q
Biol Blood Marrow Transplant; 2019 Aug; 25(8):1674-1681. PubMed ID: 31009704
[TBL] [Abstract][Full Text] [Related]
7. [Sorafenib combined with chemotherapy and donor lymphocyte infusion as salvage therapy in patients with FLT3-positive acute myeloid leukemia relapse after allogeneic hematopoietic stem cell transplantation].
Xuan L; Fan ZP; Zhang Y; Xu N; Ye JY; Zhou X; Wang ZX; Sun J; Liu QF; Huang F
Zhonghua Nei Ke Za Zhi; 2018 May; 57(5):351-354. PubMed ID: 29747291
[TBL] [Abstract][Full Text] [Related]
8. Hypomethylating Agent-Based Combination Therapies to Treat Post-Hematopoietic Stem Cell Transplant Relapse of Acute Myeloid Leukemia.
Ciotti G; Marconi G; Martinelli G
Front Oncol; 2021; 11():810387. PubMed ID: 35071015
[TBL] [Abstract][Full Text] [Related]
9. Salvage Therapy after Allogeneic Hematopoietic Cell Transplantation: Targeted and Low-Intensity Treatment Options in Myelodysplastic Syndrome and Acute Myeloid Leukemia.
Culos K; Byrne M
Clin Hematol Int; 2019 Jun; 1(2):94-100. PubMed ID: 34595416
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of venetoclax combined with hypomethylating agents for relapse of acute myeloid leukemia and myelodysplastic syndrome post allogeneic hematopoietic stem cell transplantation: a systematic review and meta-analysis.
Du Y; Li C; Zhao Z; Liu Y; Zhang C; Yan J
BMC Cancer; 2023 Aug; 23(1):764. PubMed ID: 37592239
[TBL] [Abstract][Full Text] [Related]
11. CD38-directed CAR-T cell therapy: a novel immunotherapy strategy for relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation.
Cui Q; Qian C; Xu N; Kang L; Dai H; Cui W; Song B; Yin J; Li Z; Zhu X; Qu C; Liu T; Shen W; Zhu M; Yu L; Wu D; Tang X
J Hematol Oncol; 2021 May; 14(1):82. PubMed ID: 34034795
[TBL] [Abstract][Full Text] [Related]
12. Optimizing outcomes following allogeneic hematopoietic progenitor cell transplantation in AML: the role of hypomethylating agents.
Martino M; Fedele R; Moscato T; Ronco F
Curr Cancer Drug Targets; 2013 Jul; 13(6):661-9. PubMed ID: 23713435
[TBL] [Abstract][Full Text] [Related]
13. Effect of sorafenib on the outcomes of patients with FLT3-ITD acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation.
Xuan L; Wang Y; Huang F; Jiang E; Deng L; Wu B; Fan Z; Liang X; Xu N; Ye J; Lin R; Yin C; Zhang Y; Sun J; Han M; Huang X; Liu Q
Cancer; 2018 May; 124(9):1954-1963. PubMed ID: 29509276
[TBL] [Abstract][Full Text] [Related]
14. Azacitidine and donor lymphocytes infusions in acute myeloid leukemia and myelodysplastic syndrome relapsed after allogeneic hematopoietic stem cell transplantation from alternative donors.
Liberatore C; Stanghellini MTL; Lorentino F; Vago L; Carrabba MG; Greco R; Marktel S; Assanelli A; Farina F; Corti C; Bernardi M; Peccatori J; Sockel K; Middeke JM; Schetelig J; Bergmann A; Rautenberg C; Ciceri F; Bornhäuser M; Schroeder T; Stölzel F
Ther Adv Hematol; 2022; 13():20406207221090882. PubMed ID: 35747461
[TBL] [Abstract][Full Text] [Related]
15. Treatment of FLT3-ITD-positive acute myeloid leukemia relapsing after allogeneic stem cell transplantation with sorafenib.
Sharma M; Ravandi F; Bayraktar UD; Chiattone A; Bashir Q; Giralt S; Chen J; Qazilbash M; Kebriaei P; Konopleva M; Andreeff M; Cortes J; McCue D; Kantarjian H; Champlin RE; de Lima M
Biol Blood Marrow Transplant; 2011 Dec; 17(12):1874-7. PubMed ID: 21767516
[TBL] [Abstract][Full Text] [Related]
16. Sorafenib treatment following hematopoietic stem cell transplant in pediatric FLT3/ITD acute myeloid leukemia.
Tarlock K; Chang B; Cooper T; Gross T; Gupta S; Neudorf S; Adlard K; Ho PA; McGoldrick S; Watt T; Templeman T; Sisler I; Garee A; Thomson B; Woolfrey A; Estey E; Meshinchi S; Pollard JA
Pediatr Blood Cancer; 2015 Jun; 62(6):1048-54. PubMed ID: 25662999
[TBL] [Abstract][Full Text] [Related]
17. Chemotherapy versus Hypomethylating Agents for the Treatment of Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndrome after Allogeneic Stem Cell Transplant.
Motabi IH; Ghobadi A; Liu J; Schroeder M; Abboud CN; Cashen AF; Stockler-Goldstein KE; Uy GL; Vij R; Westervelt P; DiPersio JF
Biol Blood Marrow Transplant; 2016 Jul; 22(7):1324-1329. PubMed ID: 27026249
[TBL] [Abstract][Full Text] [Related]
18. Durable remission of post-transplant relapsed FLT3-ITD AML in response to gilteritinib administration after a second transplant from the same donor.
Ando T; Sano H; Yokoo M; Kusaba K; Kidoguchi K; Yamaguchi K; Katsuya H; Yoshihara S; Kubota Y; Kojima K; Kimura S
Int J Hematol; 2020 Aug; 112(2):249-253. PubMed ID: 32185622
[TBL] [Abstract][Full Text] [Related]
19. Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trial.
Xuan L; Wang Y; Huang F; Fan Z; Xu Y; Sun J; Xu N; Deng L; Li X; Liang X; Luo X; Shi P; Liu H; Wang Z; Jiang L; Yu C; Zhou X; Lin R; Chen Y; Tu S; Huang X; Liu Q
Lancet Oncol; 2020 Sep; 21(9):1201-1212. PubMed ID: 32791048
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Feasibility of Sorafenib as a Maintenance Agent After Allogeneic Hematopoietic Stem Cell Transplantation for Fms-like Tyrosine Kinase 3 Mutated Acute Myeloid Leukemia: An Update.
Battipaglia G; Massoud R; Ahmed SO; Legrand O; El Cheikh J; Youniss R; Aljurf M; Mohty M; Bazarbachi A
Clin Lymphoma Myeloma Leuk; 2019 Aug; 19(8):506-508. PubMed ID: 31122828
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]